期刊文献+

晚期恶性肿瘤中医疗效评价指标的筛选 被引量:8

Selecting of evaluation indicator for TCM response criteria on treating advanced malignant tumor
下载PDF
导出
摘要 目的筛选晚期恶性肿瘤中医疗效标准的评价指标。方法采用中医或中西医结合治疗的晚期胃癌、晚期结直肠癌2份样本,以生存时间为因变量,以多种评价指标为自变量,进行Cox多因素回归分析,分别建立晚期胃癌、晚期结直肠癌生存预测模型,选择其独立预后因素作为晚期恶性肿瘤中医疗效标准的评价指标。结果根据Cox比例风险回归模型,晚期胃癌、晚期结直肠癌的独立预后因素均为瘤体大小、KPS评分、体质量及主症变化4项。结论瘤体大小、KPS评分、体质量及主症变化4项可作为中医疗效标准的评价指标。 Objective It is to select the evaluation indicator for TCM response criteria on treating advanced malignant tumor. Methods Two samples of advanced gastric cancer and colorectal cancer treated with TCM alone or TCM combined with western medicine were included in the study. The dependent variable was the survival time, the independent variable was the related factor, Cox model was used to analyze muhifactors, and then the survival prediction model of advanced gastric cancer and colorectal cancer were built up. The independent prognostic factors were selected as evaluation indicator for TCM response criteria on treating advanced malignant tumor. Results According to Cox regression analysis, changes in tumor size, KPS, weight and main symptoms were the four indepondent prognostic factors both in advanced gastric cancer and colorectal cancer. Conclusion Changes in tumor size, KPS, weight and main symptoms can be used as evaluation indicator for TCM response cri- teria.
出处 《现代中西医结合杂志》 CAS 2012年第36期4005-4008,共4页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 晚期恶性肿瘤 中医疗效标准 评价指标 advanced malignant tumor TCM response criteria evaluation indicator
  • 相关文献

参考文献20

二级参考文献33

  • 1陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量:34
  • 2游捷,施志明.肺积方治疗非小细胞肺癌61例临床疗效评价[J].上海中医药杂志,2005,39(6):17-20. 被引量:15
  • 3施志明.刘嘉湘扶正法治疗肿瘤学术思想初探[J].中医杂志,1996,37(12):716-718. 被引量:21
  • 4刘嘉湘.扶正法治疗122例晚期原发性非小细胞肺癌的前瞻性研究[J].中国医药学报,1987,2(1):11-13.
  • 5Wolehok JD, Hoos A, O' Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria [Jl. Clin Cancer Res, 2009, 15(23): 7412- 7420.
  • 6Hoos A, Parmiani G, Hege K,et al. A clinical development paradigm for cancer vaccines and related biologics [ J]. J Immunother, 2007, 30(1) : 1-15.
  • 7Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy [ J] ? Clin Cancer Res, 2009, 15(23) : 7116-7118.
  • 8van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells [ J ]. J Clin Oncol, 2005, 23(35): 9008-9021.
  • 9Kruit WH, van Ojik HH, Brichard VG, et al. Phase I/II study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma [J]. Int J Cancer, 2005, 117(4) : 596-604.
  • 10Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases [ J ]. Cancer Immunol Immunother, 2009, 58 ( 8 ) : 1297- 1306.

共引文献210

同被引文献68

引证文献8

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部